Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Has the Malignant Pleural Effusion Market Performed Historically, and What Are Its Future Growth Projections?
The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to the growing adoption of indwelling pleural catheters, increased focus on palliative allative care, increasing clinical trials, rising reimbursement, and rising metastatic malignancies.
The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to " $6.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing healthcare infrastructure, rising government support, increasing cancer survivors, rising demand for home-based care, growth in liquid biopsy. Major trends in the forecast period include the integration of artificial intelligence in imaging tools, advancements in targeted cancer therapies, advancements in pleurodesis, improvements in biomarkers, and expanding clinical trials for novel therapeutic agents.
Get your free report sample today:
What Are the Essential Drivers Propelling the Malignant Pleural Effusion Market Forward?
The rising cases of lung cancer is expected to propel the growth of the malignant pleural effusion market going forward. Lung cancer is a disease characterized by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and interfere with normal lung function. The rising cases of lung cancer are due to smoking and tobacco use, as prolonged exposure to harmful chemicals in cigarettes damages lung tissues, triggers genetic mutations, and promotes the uncontrolled growth of cancerous cells, significantly increasing the likelihood of developing the disease. Malignant pleural effusion indicates advanced lung cancer progression by facilitating tumor spread within the pleural cavity, leading to worsened respiratory function and a poorer prognosis. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organizations company, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the rising cases of lung cancer is driving the growth of the malignant pleural effusion market.
What Are the Primary Market Segments in the Malignant Pleural Effusion Market?
The malignant pleural effusionmarket covered in this report is segmented –
1) By Treatment: Systemic Therapy; Therapeutic Thoracentesis; Thoracic Drainage And Pleurodesis; Indwelling Pleural Catheter
2) By Diagnosis: Pleural Fluid Cytology; Immunohistochemical Tests; Imaging Tests; Pleural Thoracentosis; Pleuroscopy; Pleural Biopsy
3) By End Users: Hospitals; Ambulatory Clinics; Other End Users
Subsegments:
1) By Systemic Therapy: Chemotherapy; Targeted Therapy; Immunotherapy
2) By Therapeutic Thoracentesis: Single-Time Thoracentesis; Repeated Thoracentesis
3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis; Mechanical Pleurodesis; Biological Pleurodesis
4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter; Non-Tunneled Pleural Catheter
What Are the Current Trends Influencing the Malignant Pleural Effusion Market?
Major companies operating in the malignant pleural effusion market are focusing on developing innovative therapies such as enzyme-targeting therapy to improve treatment outcomes by targeting specific enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical approach that involves designing drugs or treatments to specifically inhibit or modify the activity of enzymes associated with diseases. This therapy is commonly used in conditions such as cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to disease progression. For instance, in September 2022, RS Oncology, LLC, a US-based biotechnology company, Initiated the MITOPE clinical trial, a first-in-human Phase 1/2 trial conducted in the United Kingdom. This study is a Phase 1/2 trial assessing RSO-021, a novel PRX3 inhibitor designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.
Who Are the Top Performers and Innovators in the Malignant Pleural Effusion Market?
Major companies operating in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH
Get the detailed malignant pleural effusion market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment